A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
Phase of Trial: Phase III
Latest Information Update: 12 Dec 2019
Price : $35 *
At a glance
- Drugs Risankizumab (Primary)
- Indications Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms IMMpact2
- Sponsors AbbVie
- 10 Dec 2019 Planned End Date changed from 27 Dec 2024 to 16 May 2024.
- 20 Mar 2019 Planned End Date changed from 1 Nov 2024 to 27 Dec 2024.
- 20 Mar 2019 Status changed from not yet recruiting to recruiting.